Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Rhea-AI Summary

Abivax (Nasdaq: ABVX) announced that 22 abstracts on obefazimod in inflammatory bowel disease were accepted for presentation at ECCO 2026 (Feb 18–21, 2026) in Stockholm. The program includes 1 oral presentation (Feb 21) reporting the first preclinical evidence of anti-fibrotic activity, 5 digital oral presentations, and 16 posters detailing subgroup analyses, biomarker changes (IL-17A, IL-6), early symptomatic improvements, and an integrated safety summary from the Phase 3 ABTECT induction trials in moderately to severely active ulcerative colitis.

The oral preclinical data address intestinal fibrosis—an unmet need in Crohn’s disease—using human small-intestinal fibroblasts and a TNBS-colitis mouse model; multiple abstracts report pooled and subgroup clinical results and safety findings from ABTECT-1 and ABTECT-2.

Key Figures

Total abstracts 22 abstracts Obefazimod data at ECCO 2026 in inflammatory bowel disease

Oral presentation 1 oral presentation Anti-fibrotic preclinical findings in inflammatory bowel disease

Digital oral presentations 5 digital oral presentations Obefazimod Phase 3 ABTECT induction trial analyses

Posters 16 posters Subgroup, biomarker, safety and PRO analyses in ulcerative colitis

Congress dates February 18–21, 2026 ECCO 21st Annual Congress in Stockholm, Sweden

Oral session time Sat, Feb 21, 08:40–08:50 Holistic IBD Care – oral anti-fibrotic preclinical presentation

Induction duration 8-week trials ABTECT-1 and ABTECT-2 Phase 3 UC induction studies

Maintenance window Week 8–48 outcomes Phase 2b open-label obefazimod maintenance study

Market Reality Check

$113.61 Last Close

Volume Volume 2,108,023 is 17% above the 20-day average of 1,802,022, indicating elevated trading interest ahead of ECCO data. normal

Technical Shares at $110.98 are trading above the 200-day MA of $50.65, but sit 19.86% below the 52-week high and well above the 52-week low of $4.77.

Peers on Argus

ABVX fell 5.88% while close peers were mixed with relatively modest moves (e.g., AXSM +0.07%, RYTM +0.93%, LEGN -1.37%, CYTK +0.06%, NUVL -1.36%). This points to a stock‑specific move rather than a broad biotech rotation.

Common Catalyst Select peers had conference and regulatory headlines today, but no shared inflammatory bowel disease or ECCO-specific catalyst appears across the peer group.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Earnings update	Neutral	-6.1%	Reported 9M 2025 results, larger cash balance and runway into Q4 2027.
Nov 03	Clinical PRO data	Positive	-3.5%	Phase 3 PRO data showed improved urgency, nocturnal symptoms and fatigue remission.
Oct 06	Phase 3 results	Positive	+3.3%	UEG pooled ABTECT results showed meaningful efficacy in multiple advanced‑therapy subgroups.
Sep 29	Abstract acceptance	Positive	+1.9%	Second late‑breaking ABTECT abstract acceptance highlighting efficacy and safety at UEG 2025.
Sep 23	Conference preview	Positive	+0.7%	Announcement of late‑breaking ABTECT efficacy presentation and related investor events at UEG.

Pattern Detected

Recent obefazimod clinical news has generally seen modestly positive price alignment, while the latest earnings update and some favorable trial data drew negative reactions.

Recent Company History

Over the last few months, Abivax has steadily built the clinical and financial story around obefazimod. Multiple 2025 UEG late‑breaking presentations from the Phase 3 ABTECT induction trials in ulcerative colitis highlighted statistically significant, clinically meaningful activity and favorable tolerability across subgroups, including patients with prior inadequate response to advanced therapies. Patient‑reported outcomes on November 3, 2025 showed quality‑of‑life gains. Financial updates on December 15, 2025 underscored a larger cash balance and runway into Q4 2027. Today’s ECCO 2026 abstract slate and new anti‑fibrotic preclinical data extend that clinical narrative.

Market Pulse Summary

This announcement underscores the depth of the obefazimod program, with 22 ECCO 2026 abstracts spanning efficacy, safety, biomarkers, and quality-of-life outcomes in ulcerative colitis, plus new anti-fibrotic preclinical data in inflammatory bowel disease. In context of prior Phase 3 ABTECT results and earlier conference presentations, it reinforces sustained clinical momentum. Investors may watch for full data at ECCO, longer-term maintenance outcomes, and any updates on regulatory or partnership plans as key future milestones.

Key Terms

ulcerative colitis medical

"moderate-to-severely active ulcerative colitis (UC)"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

Crohn's disease medical

"a critical complication in Crohn's disease (CD)"

A chronic inflammatory condition of the digestive tract in which the body's immune response causes repeated damage and irritation, leading to symptoms like abdominal pain, persistent diarrhea, weight loss and fatigue. It matters to investors because it creates ongoing demand for medications, medical devices and care services, shapes healthcare spending and insurance costs, and drives research and regulatory activity—think of it as a long-term market for treatments where an overactive security system attacks a vital pipeline.

fibrosis medical

"Fibrosis, or the excessive formation of scar tissue, is a serious complication"

Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.

strictures medical

"This scarring can lead to strictures (narrowing of the intestine)"

A stricture is an abnormal narrowing of a bodily passage, such as a blood vessel, urethra, or part of the digestive tract, that restricts normal flow or function. For investors, strictures matter because they are a target for medical treatments, devices, or procedures—like fixing a partially blocked pipe—so the prevalence, severity, and treatability of strictures can affect a healthcare product’s market size, clinical trial outcomes, and regulatory prospects.

fibroblasts medical

"an in vitro fibrosis model using human small-intestinal fibroblasts"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

TNBS-colitis medical

"in an in vivo TNBS-colitis mouse model"

An experimental laboratory method that uses a chemical called TNBS to create controlled inflammation in the colon of animals so researchers can mimic aspects of human inflammatory bowel disease. Investors watch results from TNBS-colitis studies because they serve as early proof-of-concept for new drugs or treatments — like a crash-test for a therapy — but success in this model is only an early sign and does not guarantee the same effect in human patients.

miR-124 medical

"Obefazimod enhances miR-124 expression in blood and colon tissue"

mir-124 is a tiny piece of genetic material called a microRNA that helps turn genes up or down, especially in brain and nerve cells; think of it as a thermostat that adjusts how much a gene produces. Investors care because changes in mir-124 levels can signal disease, be used as a diagnostic marker, or become a drug target—factors that can influence clinical trial results, regulatory decisions, and the commercial value of therapies.

cytokines medical

"demonstrate downregulation of pro-inflammatory cytokines (IL-17A, IL-6)"

Small proteins produced by immune and other cells that act as on/off signals or “text messages,” telling cells to ramp up, calm down, grow, or move during infection, injury, or disease. Investors watch cytokines because they are common drug targets and biomarkers—changes in cytokine activity can make a therapy work, cause serious side effects, or determine clinical trial and regulatory outcomes, all of which affect a company’s value.

AI-generated analysis. Not financial advice.

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

• Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC)
  
  
• Novel Anti-Fibrotic Preclinical Findings: Oral presentation on Saturday, February 21, 2026, “Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease," will disclose new preclinical data addressing a critical complication in Crohn's disease (CD)
  
  

PARIS, France – December 17, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that 22 scientific abstracts detailing advancements in the understanding of obefazimod for the treatment of inflammatory bowel disease (IBD) will be presented at The European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress taking place February 18-21, 2026 in Stockholm, Sweden.

Subgroup Analyses from Phase 3 ABTECT Induction Trials

The accepted abstracts, based on subgroup analyses from ABTECT Induction Trials, illustrate obefazimod’s clinical activity across a wide range of patient subpopulations, demonstrate downregulation of pro-inflammatory cytokines (IL-17A, IL-6), and highlight early symptomatic improvement along with other clinically meaningful benefits. The data also reinforces obefazimod’s favorable tolerability profile.

Obefazimod Shows First Evidence of Activity in Preclinical Fibrotic Models

The upcoming oral presentation on anti-fibrotic activity addresses a significant unmet medical need in IBD. Fibrosis, or the excessive formation of scar tissue, is a serious complication, particularly in patients with CD. This scarring can lead to strictures (narrowing of the intestine) that often necessitate surgery. To date, no efficacious anti-fibrotic treatment is available for IBD patients.

The objective of the preclinical study was to assess the anti-fibrotic effects of obefazimod in an in vitro fibrosis model using human small-intestinal fibroblasts and in an in vivo TNBS-colitis mouse model. The data from this study, titled “Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease,” will be presented during the oral presentation session on Saturday, February 21, 2026.

Marc de Garidel, Chief Executive Officer of Abivax, said “We are highly enthusiastic about the strong presence of obefazimod data at the 21st ECCO Congress, highlighting the impactful and robust data we have generated in inflammatory bowel disease. Presenting a total of 22 abstracts highlights the increasing depth of clinical understanding we have gained from the ABTECT Induction Trials in ulcerative colitis. This important data, along with the oral presentation highlighting the first evidence of anti-fibrotic activity in a preclinical model, demonstrates the potential for obefazimod to address a critical unmet need in IBD beyond inflammation.”

Fabio Cataldi, MD, Chief Medical Officer of Abivax, added, “Intestinal fibrosis is a major complication of Crohn’s disease that is not fully addressed by current therapies. This often leads to debilitating symptoms and the need for resection surgery. We look forward to sharing these new insights on obefazimod’s anti-fibrotic properties, alongside the expansive clinical data to demonstrate obefazimod’s potential efficacy and favorable safety profile in ulcerative colitis, with the IBD scientific community in Stockholm.”

Obefazimod Data to be Presented:

Date & Time	Session	Room	Abstract #	Title	Presenter
Oral Presentation
Sat, Feb 21 08:40–08:50	Holistic IBD Care - Session 10: Holistic Approach - Multidisciplinary Team	Plenary Hall	OP30	Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease	Prof. Silvio Danese, MD, PhD Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital
Digital Oral Presentations (DOP)
Fri, Feb 20 08:42–08:48	DOP Session 7: Clinical Trials II	A5	DOP057	Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials	Prof. Britta Siegmund, MD Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charite Universitätsmedizin Berlin
Fri, Feb 20 09:00–09:06	DOP Session 7: Clinical Trials II	A5	DOP060	Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 Phase 3 trials	Sonja Heeren, MD Gastroenterologist at LKH - Universitätsklinikum der PMU Salzburg, Austria
Fri, Feb 20 09:06–09:12	DOP Session 7: Clinical Trials II	A5	DOP061	Improvements in patient-reported, disease-specific and overall quality-of-life among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials	Filip Baert, MD, PhD Head of the Department of Gastroenterology at AZ Delta Hospital
Fri, Feb 20 17:51–17:57	DOP Session 12: Clinical Trials III	A5	DOP101	Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3 trials	Prof. Geert D’Haens, MD, PhD Professor of Gastroenterology at Amsterdam University Medical Centers
Fri, Feb 20 17:57–18:03	DOP Session 12: Clinical Trials III	A5	DOP102	Improvements in patient-reported fatigue among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials	Prof. Marla Dubinsky, MD Professor of Pediatrics and Medicine, Chief, Division of Pediatric Gastroenterology and Nutrition, Co-Director, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children’s Hospital, Icahn School of Medicine Mount Sinai New York
Posters
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0690	Impact of concomitant corticosteroid use on efficacy and safety of obefazimod at week 8 in moderately to severely active UC	Prof. Xavier Treton, MD, PhD Professor of Gastroenterology (MD, PhD), Paris Inflammatory Bowel Disease (IBD) Center, Centre Ambroise Pare-Hartmann, Neuilly, France
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0694	Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3 induction trials	Prof. Bruce E Sands, MD, MS Professor of Medicine, Icahn School of Medicine at Mount Sinai
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0712	Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials	Prof. Ursula Seidler, MD Professor of Internal Medicine and Gastroenterology, Hepatology, and Endocrinology; Senior Attending Physician at Medizinische Hochschule Hannover
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0713	Improvements in patient-reported bowel urgency and nocturnal bowel movements among patients with moderately to severely active UC treated with obefazimod induction therapy	Prof. Marla Dubinsky, MD Professor of Pediatrics and Medicine, Chief, Division of Pediatric Gastroenterology and Nutrition, Co-Director, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children’s Hospital, Icahn School of Medicine Mount Sinai New York
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0804	Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active UC	Prof. Raja Atreya, MD Professor of Translational Immunology in IBD Head of IBD Unit, Outpatient Clinic, Study Centre, University Hospital Erlangen
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0862	Continued efficacy improvement beyond induction with once-daily obefazimod: week 8–48 outcomes from the Phase 2b open-label maintenance study, stratified by prior advanced-therapy exposure	Alessandro Armuzzi ECCO President-Elect; Professor of Gastroenterology; Director/Leader of the IBD Unit and Co-Lead of the IBD Center, IRCCS Humanitas Research Hospital and Humanitas University, Milan, Italy
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0868	Obefazimod enhances miR-124 expression in blood and colon tissue and reduces IL-17A and IL-6 in serum of patients with moderate-to-severely active UC	Prof. Britta Siegmund, MD Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charite Universitätsmedizin Berlin
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0892	Impact of prior inadequate response to advanced therapy (ATIR) on the efficacy of obefazimod in patients with moderately to severely active UC	Filip Baert, MD, PhD Head of the Department of Gastroenterology at AZ Delta Hospital
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0894	Impact of prior advanced therapy inadequate response by drug class on symptomatic improvement with obefazimod in patients with moderately to severely active UC	Prof. Silvio Danese, MD, PhD Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0922	Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC	Prof. Fernando Magro, MD, PhD ECCO President, Consultant in Gastroenterology and Director of the Clinical Pharmacology Unit, at the São João University Hospital in Porto, Portugal
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0923	Early symptomatic improvement with obefazimod in patients with moderately to severely active UC	Prof. Alessandro Armuzzi, MD, PhD ECCO President-Elect; Professor of Gastroenterology; Director/Leader of the IBD Unit and Co-Lead of the IBD Center, IRCCS Humanitas Research Hospital and Humanitas University, Milan, Italy
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0928	Improvements in patient-reported work productivity and activity impairment among patients with moderately to severely active UC treated with obefazimod induction therapy	Prof. Britta Siegmund, MD Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charite Universitätsmedizin Berlin
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P0952	Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active UC	Prof. Laurent Peyrin-Biroulet, MD, PhD Professor of Gastroenterology, specialist in inflammatory bowel disease at Nancy University Hospital, France
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P1048	Impact of age on the efficacy and safety of once-daily oral obefazimod in moderately to severely active UC	Prof. Fernando Magro, MD, PhD ECCO President, Consultant in Gastroenterology and Director of the Clinical Pharmacology Unit, at the São João University Hospital in Porto, Portugal
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P1077	Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active UC	David T Rubin, MD Professor of Medicine and Chief, Gastroenterology, Hepatology and Nutrition at The University of Chicago
Fri, Feb 20 12:40-13:40	Guided Poster Session	Poster Exhibition Hall A	P1159	Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3 induction trials	Prof. Franco Scaldaferri, MD, PhD Gastroenterologist, endoscopist Director of the Chronic Inflammatory Bowel Diseases Unit, IBD UNIT At the CEMAD UOC (Center for Digestive System Diseases) Gemelli Polyclinic Foundation IRCSS - Catholic University Of The Sacred Heart Dipartimento Di Medicina E Chirurgia Traslazionale, Università Cattolica Del Sacro Cuore, Roma

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications
Karissa Cross, Ph.D.
Account Supervisor
kcross@lifescicomms.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “potential,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company’s preclinical study results of obefazimod and the potential therapeutic benefit of obefazimod. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

FAQ

What will Abivax (ABVX) present at ECCO 2026 and when is the oral presentation?

Abivax will present 22 abstracts at ECCO 2026; the oral presentation on anti-fibrotic preclinical findings is on Feb 21, 2026 at 08:40–08:50.

What is the focus of the oral presentation on obefazimod at ECCO 2026 (ABVX)?

The oral talk will disclose the first preclinical evidence that obefazimod shows anti-fibrotic activity in human small-intestinal fibroblast models and a TNBS-colitis mouse model.

How many obefazimod abstracts at ECCO 2026 report Phase 3 ABTECT data (ABVX)?

Multiple abstracts—including 5 digital oral presentations and 16 posters—present subgroup and pooled analyses from the ABTECT-1 and ABTECT-2 Phase 3 induction trials.

Which biomarkers did Abivax report as downregulated by obefazimod in ABTECT analyses (ABVX)?

The abstracts report downregulation of pro-inflammatory cytokines, specifically IL-17A and IL-6, in pooled analyses from the ABTECT trials.

Will Abivax present safety and quality-of-life findings for obefazimod at ECCO 2026 (ABVX)?

Yes; accepted presentations include an integrated safety summary, analyses on patient-reported outcomes, fatigue, work productivity, and early symptomatic improvement.

Where and when is ECCO 2026 where Abivax (ABVX) will present obefazimod data?

ECCO 2026 takes place in Stockholm, Sweden, Feb 18–21, 2026, and Abivax presentations are scheduled across Feb 20–21 sessions.